These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

476 related items for PubMed ID: 7496840

  • 21. EGFR, HER-2/neu, cyclin D1, p21 and p53 in correlation to cell proliferation and steroid hormone receptor status in ductal carcinoma in situ of the breast.
    Lebeau A, Unholzer A, Amann G, Kronawitter M, Bauerfeind I, Sendelhofert A, Iff A, Löhrs U.
    Breast Cancer Res Treat; 2003 May; 79(2):187-98. PubMed ID: 12825853
    [Abstract] [Full Text] [Related]

  • 22. Routine assessment of hormonal receptor and her-2/neu status underscores the need for more therapeutic targets in Kenyan women with breast cancer.
    Nyagol J, Nyong'o A, Byakika B, Muchiri L, Cocco M, de Santi MM, Spina D, Bellan C, Lazzi S, Kostopoulos I, Luzi P, Leoncini L.
    Anal Quant Cytol Histol; 2006 Apr; 28(2):97-103. PubMed ID: 16637512
    [Abstract] [Full Text] [Related]

  • 23. In microdissected ductal carcinoma in situ, HER-2/neu amplification, but not p53 mutation, is associated with high nuclear grade and comedo histology.
    Ho GH, Calvano JE, Bisogna M, Borgen PI, Rosen PP, Tan LK, Van Zee KJ.
    Cancer; 2000 Dec 01; 89(11):2153-60. PubMed ID: 11147584
    [Abstract] [Full Text] [Related]

  • 24. Expression and amplification of cyclin D1 in primary breast carcinomas: relationship with histopathological types and clinico-pathological parameters.
    Naidu R, Wahab NA, Yadav MM, Kutty MK.
    Oncol Rep; 2002 Dec 01; 9(2):409-16. PubMed ID: 11836618
    [Abstract] [Full Text] [Related]

  • 25. AgNOR analysis of atypical ductal hyperplasia and intraductal carcinoma of the breast.
    Guski H, Hufnagl P, Kaufmann O, Krause M, Winzer KJ.
    Anal Quant Cytol Histol; 2000 Jun 01; 22(3):206-12. PubMed ID: 10872036
    [Abstract] [Full Text] [Related]

  • 26. Associations between the standardized uptake value of (18)F-FDG PET/CT and the prognostic factors of invasive lobular carcinoma: in comparison with invasive ductal carcinoma.
    Jung NY, Kim SH, Choi BB, Kim SH, Sung MS.
    World J Surg Oncol; 2015 Mar 15; 13():113. PubMed ID: 25889560
    [Abstract] [Full Text] [Related]

  • 27. Comedo-DCIS is a precursor lesion for basal-like breast carcinoma: identification of a novel p63/Her2/neu expressing subgroup.
    Shekhar MP, Kato I, Nangia-Makker P, Tait L.
    Oncotarget; 2013 Feb 15; 4(2):231-41. PubMed ID: 23548208
    [Abstract] [Full Text] [Related]

  • 28. Breast infiltrating ductal carcinoma: analysis of hormone, HER-2 receptors and Ki-67 proliferation marker.
    Mustać E, Zamolo G, Petković M, Dordević G, Radić J, Grgurević E, Batinac T.
    Coll Antropol; 2008 Sep 15; 32(3):741-6. PubMed ID: 18982746
    [Abstract] [Full Text] [Related]

  • 29. Morphological profile and association of HER-2/neu with prognostic markers in breast carcinoma in Northern Pakistan.
    Sharif MA, Mamoon N, Mushtaq S, Khadim MT.
    J Coll Physicians Surg Pak; 2009 Feb 15; 19(2):99-103. PubMed ID: 19208313
    [Abstract] [Full Text] [Related]

  • 30. Cell proliferation, nuclear ploidy, and EGFr and HER2/neu tyrosine kinase oncoproteins in infiltrating ductal breast carcinoma.
    Fernández Val JF, Losada J, Arregui Murua MA, Sarría R.
    Cancer Genet Cytogenet; 2002 Oct 01; 138(1):69-72. PubMed ID: 12419588
    [Abstract] [Full Text] [Related]

  • 31. Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast.
    Steinman S, Wang J, Bourne P, Yang Q, Tang P.
    Ann Clin Lab Sci; 2007 Oct 01; 37(2):127-34. PubMed ID: 17522367
    [Abstract] [Full Text] [Related]

  • 32. Prognostic Significance of Progesterone Receptor Expression in Estrogen-Receptor Positive, HER2-Negative, Node-Negative Invasive Breast Cancer With a Low Ki-67 Labeling Index.
    Ono M, Tsuda H, Yoshida M, Shimizu C, Kinoshita T, Tamura K.
    Clin Breast Cancer; 2017 Feb 01; 17(1):41-47. PubMed ID: 27477822
    [Abstract] [Full Text] [Related]

  • 33. Correlation of HER-2/neu protein overexpression with other prognostic and predictive factors in invasive ductal breast cancer.
    Ivkovic-Kapicl T, Knezevic-Usaj S, Djilas-Ivanovic D, Panjkovic M.
    In Vivo; 2007 Feb 01; 21(4):673-8. PubMed ID: 17708365
    [Abstract] [Full Text] [Related]

  • 34. Breast density, scintimammographic (99m)Tc(V)DMSA uptake, and calcitonin gene related peptide (CGRP) expression in mixed invasive ductal associated with extensive in situ ductal carcinoma (IDC + DCIS) and pure invasive ductal carcinoma (IDC): correlation with estrogen receptor (ER) status, proliferation index Ki-67, and histological grade.
    Papantoniou V, Sotiropoulou E, Valsamaki P, Tsaroucha A, Sotiropoulou M, Ptohis N, Stipsanelli A, Dimitrakakis K, Marinopoulos S, Tsiouris S, Antsaklis A.
    Breast Cancer; 2011 Oct 01; 18(4):286-91. PubMed ID: 20143189
    [Abstract] [Full Text] [Related]

  • 35. [ErbB-2 expression and hormone receptor status in areas of transition from in situ to invasive ductal breast carcinoma].
    Peres RM, Derchain SF, Heinrich JK, Serra KP, Pinto GA, Soares FA, Sarian LO.
    Rev Bras Ginecol Obstet; 2009 Sep 01; 31(9):461-7. PubMed ID: 19876578
    [Abstract] [Full Text] [Related]

  • 36. Expression of E-cadherin and c-erbB-2/HER-2/neu oncoprotein in high-grade breast cancer.
    Turashvili G, Bouchalova K, Bouchal J, Kolar Z.
    Cesk Patol; 2007 Jul 01; 43(3):87-92. PubMed ID: 17821836
    [Abstract] [Full Text] [Related]

  • 37. Expression of HER-2/NEU oncoprotein in familial and non-familial breast cancer.
    Tsai KB, Hou MF, Lin HJ, Chai CY, Liu CS, Huang TJ.
    Kaohsiung J Med Sci; 2001 Feb 01; 17(2):64-76. PubMed ID: 11416960
    [Abstract] [Full Text] [Related]

  • 38. Usefulness of 18F-FDG uptake with clinicopathologic and immunohistochemical prognostic factors in breast cancer.
    Kim BS, Sung SH.
    Ann Nucl Med; 2012 Feb 01; 26(2):175-83. PubMed ID: 22139552
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. HER-2/neu overexpression as a predictor for the transition from in situ to invasive breast cancer.
    Roses RE, Paulson EC, Sharma A, Schueller JE, Nisenbaum H, Weinstein S, Fox KR, Zhang PJ, Czerniecki BJ.
    Cancer Epidemiol Biomarkers Prev; 2009 May 01; 18(5):1386-9. PubMed ID: 19383888
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 24.